퍼제타(Perjeta) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Perjeta Market Growth & Trends:

The global perjeta market is anticipated to reach USD 5.93 billion by 2030 and is projected to grow at a CAGR of 5.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market for Perjeta (pertuzumab), a monoclonal antibody developed by F. Hoffmann-La Roche Ltd, continues to show strong momentum in the treatment of HER2-positive breast cancer, particularly in early-stage and metastatic settings. As part of combination therapies, Perjeta has demonstrated improved outcomes in both neoadjuvant and metastatic treatment regimens, solidifying its role in comprehensive breast cancer care. The drug's mechanism of action-targeting the HER2 receptor to inhibit cancer cell growth-has made it a cornerstone in modern oncology protocols.

Perjeta is commonly used in conjunction with trastuzumab and chemotherapy, and its efficacy in reducing the risk of disease recurrence in early breast cancer, as well as extending progression-free survival in metastatic cases, has been backed by robust clinical data. The continued rise in breast cancer incidence, along with growing awareness and early diagnosis initiatives, is driving increased demand for effective biologic therapies such as Perjeta.

Hospital pharmacies remain central to Perjeta's distribution, particularly during the initial phases of treatment, where medical supervision and infusion infrastructure are necessary. As patients progress through their treatment journey, specialty pharmacies play a growing role by offering services tailored to oncology patients, including infusion coordination, personalized care management, and adherence support. These pharmacies help ensure that patients undergoing complex biologic therapies maintain consistent access to treatment.

Although Perjeta is currently a branded therapy, the future introduction of a generic or biosimilar version could significantly reshape the market. The availability of more cost-effective alternatives would enhance accessibility and relieve some of the financial burden associated with long-term cancer treatment. This would be particularly impactful in emerging markets and health systems under pressure to balance innovation with affordability.

As with other biologic therapies, supply chain efficiency and cold chain logistics remain critical to maintaining drug quality and availability. The growing role of specialty and online pharmacies, combined with advancements in digital health and patient management platforms, offers opportunities to overcome these challenges and improve the overall patient experience.

The demand for advanced therapies like Perjeta reflects a broader shift toward precision medicine in oncology. With breast cancer remaining one of the most prevalent cancers worldwide, the need for targeted, effective treatment options is stronger than ever. Continued innovation by companies like F. Hoffmann-La Roche Ltd, along with strategic partnerships across hospital and pharmacy networks, will be key in meeting this demand and improving outcomes for breast cancer patients globally.

Perjeta Market Report Highlights:

• Based on product, the monoclonal antibody segment dominated the market in 2024, solidifying its position as the preferred treatment option for breast cancer management. Perjeta is a targeted monoclonal antibody therapy, offering high specificity and effectiveness against HER2-positive breast cancer, making it the dominant drug class in this market segment.
• Based on indication, metastatic breast cancer segment dominated the Perjeta market in 2024. Its proven ability to extend progression-free and overall survival in metastatic HER2-positive breast cancer makes this indication the primary driver of Perjeta's demand.
• Based on distribution channel, hsopital pharmacies emerged as the dominant distribution channel in 2024. Due to the need for intravenous administration and close medical supervision, hospital pharmacies are the main distribution channel for Perjeta.
• North America led the Perjeta market, attributed to factors such as a well-established healthcare infrastructure, high awareness of about disease, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.
• Companies operating in the Perjeta market include F. Hoffmann-La Roche Ltd, Ambrx Biopharma, Carisma Therapeutics, and Byondis.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Indication
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Perjeta Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
    • 3.3.3.1. Phase 1
    • 3.3.3.2. Phase 2
    • 3.3.3.3. Phase 3
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Perjeta Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Monoclonal Antibody
  • 4.4.1. Monoclonal Antibody Market, 2018 - 2030 (USD Million)
• 4.5. Generic Drug
  • 4.5.1. Generic Drug Market, 2018 - 2030 (USD Million)

Chapter 5. Perjeta Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Early Breast Cancer
  • 5.4.1. Early Breast Cancer Market, 2018 - 2030 (USD Million)
• 5.5. Metastatic Breast Cancer
  • 5.5.1. Metastatic Breast Cancer Market, 2018 - 2030 (USD Million)

Chapter 6. Perjeta Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Specialty Pharmacies
  • 6.5.1. Specialty Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Other Pharmacies
  • 6.6.1. Other Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Perjeta Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 7.4. North America
  • 7.4.1. North America Perjeta Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Perjeta Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Perjeta Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. F. Hoffmann-La Roche Ltd
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Ambrx Biopharma
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Carisma Therapeutics
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Byondis
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives